The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force TÜBINGEN, Germany/ Boston - March 02, 2020 - Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak's response. In the discussion, Menichella highlighted the potential of CureVac's mRNA platform for vaccine development based on mRNA technology. "We are very confident that we will be able to develop a potent vaccine candidate within a few months, said CureVac CEO Daniel Menichella. "We can rely on the data of a Phase 1 rabies study in which we were able to immunize all participants with a very low dose. On this basis, we are working intensively to achieve a very low dose for the CoV vaccine as well. In addition, CureVac has a GMP-certified production facility which enables us to produce up to ten million vaccine doses in one production run."
TÜBINGEN, Germany/ Boston - March 02, 2020 - Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak's response.
In the discussion, Menichella highlighted the potential of CureVac's mRNA platform for vaccine development based on mRNA technology. "We are very confident that we will be able to develop a potent vaccine candidate within a few months, said CureVac CEO Daniel Menichella. "We can rely on the data of a Phase 1 rabies study in which we were able to immunize all participants with a very low dose. On this basis, we are working intensively to achieve a very low dose for the CoV vaccine as well. In addition, CureVac has a GMP-certified production facility which enables us to produce up to ten million vaccine doses in one production run."
○ Paul-Ehrlich-Institut (PEI), the Federal Institute for Vaccines and Biomedicines
Today's news ...
○ Trump was doing everything he could to secure a vaccine for the United States | DW |
Yep ... the Coronavirus may cost the Republicans and Trump the election in Nov.2020.
My earlier post @TikunOlam:
by gmoke - Nov 30
by gmoke - Nov 24
by gmoke - Nov 7
by gmoke - Nov 11
by Oui - Dec 12
by Oui - Dec 11
by Oui - Dec 10
by Oui - Dec 9
by Oui - Dec 8
by Oui - Dec 7
by Oui - Dec 6
by Oui - Dec 61 comment
by Oui - Dec 51 comment
by Oui - Dec 4
by Oui - Dec 3
by Oui - Dec 312 comments
by Oui - Dec 2
by Oui - Dec 1